Core Viewpoint - The pharmaceutical sector is experiencing increased merger and acquisition activity, alongside strong product pipelines, which may present renewed investment opportunities, particularly for those focusing on free cash flow metrics [1]. Group 1: Pharmaceutical Industry Outlook - The pharmaceutical industry is seeing a ramp-up in M&A activity and has robust pipelines with significant product launches anticipated [1]. - Factors such as interest rate cuts and potential deregulation may improve sentiment towards pharmaceutical companies [4]. - Merck & Co Inc. (MRK) is highlighted as a top holding in the VictoryShares Free Cash Flow ETF (VFLO), indicating its potential for upside [2]. Group 2: Free Cash Flow (FCF) Importance - Free cash flow is a critical metric for assessing a company's financial strength, revealing cash remaining after operating expenses [3]. - As of the end of 2025, MRK demonstrated strong FCF generation, contributing to its status as the largest holding in VFLO [4]. - The Victory U.S. Large Cap Free Cash Flow Index screens companies based on expected FCF, focusing on both trailing and forward-looking measures [5]. Group 3: Merck's Performance - Merck's Q4 results exceeded estimates, with the CEO expressing a positive outlook for 2026, driven by demand for innovative products like KEYTRUDA and contributions from new launches [2][3]. - The company's performance in various segments, including cardiometabolic, respiratory, and vaccines, has bolstered its financial results [3].

Core Insights - Infinimmune has entered a partnership with Merck that could be valued at approximately $838 million in milestone payments for the discovery and development of multiple antibodies targeting undisclosed diseases [1][2]. Group 1: Partnership Details - The agreement includes an undisclosed upfront payment to Infinimmune, with potential milestone payments linked to various drug candidates totaling up to $838 million [2]. - Merck will hold exclusive rights to develop and commercialize the antibody candidates resulting from this collaboration [2]. Group 2: Technology and Focus - Infinimmune will utilize its proprietary platform to screen a large number of human immune cells to identify naturally occurring antibodies, employing AI tools for refinement and enhancement [3]. - The specific disease targets selected by Merck for this partnership have not been disclosed [3]. Group 3: Additional Developments - Apart from the collaboration with Merck, Infinimmune is also working on its own early-stage medicines aimed at treating moderate-to-severe eczema and other immune-related diseases [4].

Merck's drug reduced bad cholesterol by 64.6% in late-stage trial | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Financecategory· March 30, 2026 · 3:45 PM UTC · ago Federal Reserve Chair Jerome Powell said on Monday the U.S. central bank is watching developments in the private credit sector for signs of trouble, but does not currently see issues there bringing down the financial system as a whole. The Merck logo is seen at a gate to the Merck & Co ca ...

The Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD) has a very simple strategy. It tracks an index that aims to hold the top 100 high-yielding dividend stocks. That index reshuffles its holdings once a year to ensure it contains only the best of the best. The fund recently completed its annual reconstitution. One of the more notable changes was an increase in its allocation to high-yielding dividend stocks in the healthcare sector. Here's a closer look at some of the fund's recent changes. Will AI create t ...

Core Insights - Merck announced a significant acquisition worth $15 billion, marking it as the second-largest deal in recent times, aimed at enhancing its pipeline appeal [1] Group 1: Acquisition Details - The acquisition by Merck is intended to invigorate its product pipeline, indicating a strategic move to strengthen its market position [1] - This deal is part of a broader trend where companies are engaging in major mergers and acquisitions to capitalize on growth opportunities [1] Group 2: Investment Opportunities - The investing group "Value in Corporate Events" focuses on identifying actionable ideas from major corporate events such as earnings reports, M&A, and IPOs, providing members with insights into potential investment opportunities [1] - The group covers approximately 10 major events each month, aiming to find the best opportunities for investors [1]

Jim Cramer reviewed Pfizer Inc. (NYSE:PFE) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. Cramer mentioned the stock during the episode and said: In a slowdown, the hedge fund playbook says you want safety stocks. The stocks of companies that will make good money even if the broader economy deteriorates dramatically, the opposite of cyclical stocks. For example, big pharma. Now, if you need a medication, you’ll keep taking it in good times and bad. You don’t ...

Core Viewpoint - Johnson & Johnson's Innovative Medicine segment is expected to show growth in Q1 2026, driven by key product sales despite challenges from the loss of exclusivity of Stelara and competitive pressures from biosimilars [1][10]. Sales Performance - The Innovative Medicine unit's sales increased by 4.1% on an organic basis in 2025, even with the loss of exclusivity for Stelara and the negative impact of the Part D redesign [2]. - The segment achieved over $15 billion in sales for three consecutive quarters in 2025, a trend anticipated to continue into Q1 2026 [2]. Key Product Contributions - Growth in Q1 2026 is expected to be supported by increased sales of Darzalex, Tremfya, and Erleada, along with market share gains and expansion [3]. - Newer therapies such as Carvykti, Tecvayli, Talvey, Rybrevant, Lazcluze, Caplyta, and Spravato are also projected to contribute to overall growth [3]. Competitive Landscape - The launch of several biosimilar versions of Stelara in 2025 negatively impacted the Innovative Medicines segment's growth by 10.4% [5]. - Imbruvica sales are expected to decline due to rising competition, and the Part D redesign is anticipated to further affect sales of Stelara, Imbruvica, and Erleada [6]. New Product Developments - Investors are keen on commercialization plans and initial sales figures for newly approved products like Inlexzoh/TAR-200 and Imaavy [7]. - The FDA recently approved Icotyde for treating moderate-to-severe plaque psoriasis, although it will not contribute to Q1 2026 sales [8]. Market Position and Valuation - J&J's shares have outperformed the industry, rising 46.2% over the past year compared to the industry's 10.6% increase [11]. - The company's shares are trading at a forward price/earnings ratio of 20.36, higher than the industry average of 16.99 and above its five-year mean of 15.65 [13]. Earnings Estimates - The Zacks Consensus Estimate for 2026 earnings remains stable at $11.54 per share, while the estimate for 2027 has increased from $12.33 to $12.44 [15]. - Current estimates for Q1 and Q2 2026 are $2.69 and $2.93 per share, respectively [16].

Core Insights - Merck is actively pursuing mergers and acquisitions to enhance its pipeline and ensure long-term growth, particularly in oncology and immunology [1] - The recent acquisition of Terns Pharmaceuticals for $6.7 billion is part of Merck's strategy to diversify its portfolio and secure next-generation therapies [2][11] Acquisition Details - Merck has agreed to acquire Terns Pharmaceuticals at $53.00 per share, with the deal expected to close in Q2 2026 [2] - The acquisition will expand Merck's hematology/cancer pipeline by adding Terns' lead candidate, TERN-701, which is in phase I/II studies for chronic myeloid leukemia [3] Product Pipeline and Strategy - TERN-701 has received Orphan Drug designation from the FDA and is believed to offer a differentiated treatment option for chronic myeloid leukemia [4] - Merck's acquisition strategy includes previous deals such as Cidara Therapeutics for $9.2 billion and Verona Pharma for around $10 billion, focusing on innovative treatments [5][6] Competitive Landscape - Merck's acquisitions aim to reduce reliance on Keytruda, which currently accounts for over half of its pharmaceutical sales and is expected to face biosimilar competition around 2028-2029 [8][9][11] - Keytruda's competitive pressure may increase from dual PD-1/VEGF inhibitors, which could impact its market position [9] Financial Performance - Year-to-date, Merck's shares have increased by 13%, outperforming the industry, which has declined by 3.4% [14] - Merck's shares are trading at a premium with a price/earnings ratio of 18.27 compared to the industry average of 16.99 [15] Earnings Estimates - The Zacks Consensus Estimate for 2026 earnings per share has decreased from $6.55 to $5.47, and for 2027 from $10.07 to $9.89 over the past 60 days [18]

Core Insights - Merck's stock has increased by 51.4% over the past six months, driven by an optimistic outlook for long-term growth following the patent expiration of its key drug, Keytruda, in 2028 [1][9] - The company is enhancing its pipeline through recent M&A activities and new product launches, which bolsters confidence in its growth prospects post-Keytruda [2][6] Group 1: Keytruda's Impact - Keytruda is Merck's most significant product, accounting for approximately 55% of pharmaceutical sales, with sales reaching $31.7 billion in 2025, a 7% increase year-over-year [3][5] - The drug's sales are expected to peak at $35 billion by 2028, with continued growth anticipated until patent expiration [5][16] - Merck is exploring innovative strategies to sustain Keytruda's growth, including new immuno-oncology combinations and a personalized mRNA therapeutic cancer vaccine in collaboration with Moderna [4][11] Group 2: Pipeline and M&A Activities - Merck's drug pipeline has nearly tripled since 2021, supported by both internal development and acquisitions, with promising candidates like Capvaxive and Winrevair showing strong market potential [7][10] - Recent acquisitions, including Verona and Cidara Therapeutics, have added valuable products to Merck's portfolio, enhancing its long-term growth outlook [11][12] - The company has announced a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, which will add a candidate for chronic myeloid leukemia to its pipeline [13] Group 3: Challenges and Market Dynamics - Sales of Gardasil, Merck's second-largest product, have declined significantly, with a 39% drop in 2025 due to weak demand in China and Japan [14][16] - The company faces potential revenue losses from generic competition for several products, including Januvia and Bridion, with an estimated impact of approximately $2.5 billion in 2026 [18][19] - Despite the challenges, Merck anticipates over $70 billion in potential commercial opportunities from its current pipeline by the mid-2030s, which is significantly higher than the peak sales estimate for Keytruda [29][30]

Core Insights - Tempus AI (TEM) is expanding its presence in 2026 through strategic collaborations with pharmaceutical companies, healthcare institutions, and technology innovators to enhance data-driven insights for clinical outcomes and drug development [1] Group 1: Strategic Collaborations - Tempus has partnered with Daiichi Sankyo to accelerate the clinical development of an antibody drug conjugate (ADC) program in oncology, utilizing Tempus' PRISM2 AI models [2] - The company has integrated Median Technologies' eyonis LCS solution into the Tempus Pixel platform for non-invasive characterization of lung nodules, improving clinical decision-making [3] - A collaboration with Blood Cancer United aims to create a patient-centered registry for pediatric acute myeloid leukemia (pAML), leveraging Tempus' AI-enabled health concierge app and cloud-based analytics [4] - Tempus has formed a multi-year strategic collaboration with NYU Langone Health to enhance cancer care through advanced molecular profiling and data-driven insights [4] Group 2: Industry Updates - Guardant Health, Inc. has entered a multi-year collaboration with Merck to support the development of Merck's oncology portfolio using Guardant's Smart platform [5][6] - 10x Genomics, Inc. announced that a research consortium will utilize its Xenium spatial platform to create a comprehensive multimodal cancer dataset [7] - BioTuring and 10x Genomics have collaborated to streamline single-cell and spatial data analysis, enhancing analytical capabilities [8] Group 3: Stock Performance and Valuation - Tempus' shares have increased by 12.2% over the past year, contrasting with a 29.5% decline in the industry, while the S&P 500 has improved by 17.6% [9] - The current forward Price-to-Sales (P/S) ratio for TEM is 4.98X, lower than the industry median of 5.34X, indicating a relatively cheap valuation [11] - The loss per share estimate for 2026 has widened to 32 cents from 18 cents over the past 30 days [12]